-52%

est. 2Y upside i

HealthcareSeries B

Rank

#1449

Sector

Healthtech / AI in Oncology

Est. Liquidity

~3Y

Data Quality

Data: Medium

C the Signs operates in a high-growth, impactful sector with a proven product in the UK's NHS.

Last updated: March 10, 2026

Bull (25%)+250%

C the Signs achieves rapid and widespread adoption in the U.S. market, securing key partnerships with major healthcare systems beyond Mayo Clinic and navigating FDA pathways efficiently. This, combined with continued strong performance in the NHS and expansion into detecting a broader range of cancers, drives revenue to over $100M by 2028, justifying a $350M+ valuation at a 3.5x multiple on current valuation.

Base (45%)+50%

The company maintains its strong position and growth trajectory within the UK's NHS, steadily expanding its user base and demonstrating consistent efficacy. U.S. market entry is slower than anticipated due to regulatory complexities and competition, but C the Signs secures initial traction. Revenue grows to approximately $50M by 2028, leading to a $150M valuation.

Bear (30%)-60%

U.S. expansion faces significant delays and hurdles with FDA approval, while dominant incumbents like Tempus or major EHR providers (Epic, Cerner) integrate similar AI-powered early detection features, eroding C the Signs' competitive edge. Growth stalls, leading to a down round or acquisition at a significantly lower valuation of $40M, wiping out most common stock value given the preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $21M in liquidation preferences ahead of common stock, representing 21% of the estimated $100M post-money valuation.

Dilution Risk

moderate

As a Series B company, C the Signs will likely require at least one to two more funding rounds (Series C, D) before a potential exit, leading to further dilution for current equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for C the Signs' equity at this stage.

Questions to Ask at the Interview

Strategic questions based on Cthesigns's data — designed to show you've done your homework.

  • 1

    “Given the strong incumbent presence of companies like Epic and Cerner in the U.S. EHR market, what is C the Signs' strategy to integrate and gain market share effectively?”

  • 2

    “With the goal of expanding to the U.S., how is the company prioritizing FDA regulatory pathways and building out its U.S. team and partnerships?”

  • 3

    “Considering the Series B funding and the typical timeline for healthtech exits, what is the company's anticipated liquidity event timeline for employees, and how is dilution being managed for future rounds?”

Community

Valuation Sentiment

Our model estimates -52% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.